Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis to Add Oncology Drugs to Infectious Disease and NASH Portfolios

publication date: Mar 30, 2021

Hangzhou's Ascletis Pharma announced that it will expand its focus into oncology. The company was founded to bring effective hepatitis C treatments to China at an affordable price. It has accomplished that, and it now plans to combine its two in-licensed FASN inhibitors with two self-discovered anti-cancer drugs, an EGFR anti-angiogenesis candidate (bevacizumab) and a small molecule PD-1 inhibitor. Initially, it will test a combination of ASC40 and bevacizumab in patients with astrocytoma, a cancer of the brain or spinal cord. More details.....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.